Lenalidomide is a generic pharmaceutical product developed for the oncology segment, specifically indicated for the treatment of multiple myeloma. This capsule formulation has been launched in the US market, reflecting its compliance with regulatory requirements for that jurisdiction. As a generic alternative, it serves as a cost-effective option for sourcing buyers involved in the supply of oncology therapies.
The product is manufactured by Lotus Pharmaceutical, a company based in Tashkent, Uzbekistan, with an operational history dating back to 1966. This manufacturer’s long-standing presence in the pharmaceutical industry supports the product’s availability for international distribution. Lenalidomide capsules are commonly sourced by buyers seeking to address the needs of healthcare systems and treatment programs for multiple myeloma patients, requiring careful handling and cold-chain logistics typical of oncology pharmaceuticals.